News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904Next Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories News Perpetuals.com Launches Strategic Initiative to Deploy Next-Generation Agentic AI Infrastructure Platform for Fintech and Digital Assets Industry; Secures Exclusive License for Proprietary On-Premises Quantitative Research Platform “Forgentiq.ai” News Perpetuals.com Launches Strategic Initiative to Deploy Next-Generation Agentic AI Infrastructure Platform for Fintech and Digital Assets Industry; Secures Exclusive License for Proprietary On-Premises Quantitative Research Platform “Forgentiq.ai” News SVT Robotics Introduces SOFTBOT® Intelligence; Powering the Data Backbone for Enterprise and Physical AI News EmpowerFresh Deploys AI Produce Ordering Platform at Kowalski’s Markets in Minnesota News SVT Robotics Introduces SOFTBOT® Intelligence; Powering the Data Backbone for Enterprise and Physical AI News UltiSim launches Data Fusion Plane, bringing optimal AI infrastructure to mid-market enterprise and government market
